2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

peptide drug conjugate

" in MedChemExpress (MCE) Product Catalog:

24

Inhibitors & Agonists

1

Biochemical Assay Reagents

10

Peptides

1

Inhibitory Antibodies

1

Natural
Products

1

Click Chemistry

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19813A
    mDPR-Val-Cit-PAB-MMAE TFA

    		Drug-Linker Conjugates for ADC Cancer
    mDPR-Val-Cit-PAB-MMAE TFA is a drug-linker conjugate for ADC (Drug-Linker Conjugates for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and an ADC linker (peptide Val-Cit- PAB) composition [1] .
    mDPR-Val-Cit-PAB-MMAE TFA
  • HY-164166
    Fmoc-Sar-Sar-Sar-OH

    		Biochemical Assay Reagents Others
    Fmoc-Sar-Sar-Sar-OH is a small molecule polypeptide composed of four sarcosine residues, in which the N-terminus of the peptide chain is protected by Fmoc. Fmoc-Sar-Sar-Sar-OH can be used for peptide synthesis or synthesis of drug-peptide ligand conjugates .
    Fmoc-Sar-Sar-Sar-OH
  • HY-153395
    PH-HG-005-5

    		Drug-Linker Conjugates for ADC Cancer
    PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .
    PH-HG-005-5
  • HY-13631E
    Deruxtecan
    Maximum Cited Publications
    12 Publications Verification

    MC-GGFG-DXD

    		 Drug-Linker Conjugates for ADC Cancer
    Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan
  • HY-113003
    H-γ-Glu-Gln-OH

    γ-Glutamylglutamine; γ-Glu-Gln

    		 Others Others Cancer
    H-γ-Glu-Gln-OH is a hydrophilic peptide and can be conjugated to drugs. The carrier composed of H-γ-Glu-Gln-OH has the characteristics of high water solubility and drug-loading capacity, good biocompatibility, low toxicity, improved tumor targeting ability, and anti-tumor efficacy .
    H-γ-Glu-Gln-OH
  • HY-P10741
    DOTA-EB-TATE

    		Radionuclide-Drug Conjugates (RDCs) Somatostatin Receptor Cancer
    DOTA-EB-TATE is composed of SST peptide derivative, DOTA-octreotate conjugated a common to an Evans blue analog (EB). DOTA-EB-TATE is a peptide drug conjugate (PDC) improves the pharmacokinetics of SSTR2 analogs and reduces PRRT toxicity .
    DOTA-EB-TATE
  • HY-129360
    Ala-Ala-Asn-PAB

    		ADC Linker Cancer
    Ala-Ala-Asn-PAB is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .
    Ala-Ala-Asn-PAB
  • HY-129360A
    Ala-Ala-Asn-PAB TFA

    		ADC Linker Cancer
    Ala-Ala-Asn-PAB TFA is a peptide cleavable ADC linker for antibody-drug conjugates (ADCs) .
    Ala-Ala-Asn-PAB TFA
  • HY-147021
    MC-Val-D-Cit-PAB-PNP

    		ADC Linker Cancer
    MC-Val-D-Cit-PAB-PNP is a cleavable peptide linker molecule used in the synthesis of antibody-drug conjugates (ADCs). MC-Val-D-Cit-PAB-PNP contains a maleimidocaproyl (Mc) group that can be conjugated to an antibody and a p-nitrophenol (PNP) group that allows the peptide to be linked to antitumor compounds.
    MC-Val-D-Cit-PAB-PNP
  • HY-150241
    DOPE-NHS

    		Liposome Others
    DOPE-NHS is a linker. DOPE-NHS can be used for peptides to be conjugated to exosomes and possibly other membrane-based nanoparticles. DOPE-NHS can be used for drug delivery .
    DOPE-NHS
  • HY-P10742
    CBX-12

    		Peptide-Drug Conjugate (PDC) Topoisomerase Cancer
    CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631) .
    CBX-12
  • HY-P10740
    CBP-1018

    		Peptide-Drug Conjugate (PDC) TRP Channel Cancer
    CBP-1018 is a PDC (peptide-drug conjugate) formed by dual ligands targeting FRα/TRPV6 conjugated with Monomethyl auristatin E (HY-15162) through a linker (HY-78738). CBP-1018 holds potential for research in the field of breast cancer .
    CBP-1018
  • HY-P99881
    Rolinsatamab talirine

    ABBV 176

    		 Drug-Linker Conjugates for ADC Cancer
    Rolinsatamab talirine (ABBV 176) is an antibody-drug conjugate (ADC) targeting prolactin receptor (PRLR). Rolinsatamab talirine consists of rolinsatamab (HY-P99238), an enzymatically cleavable peptide linker, and SGD-1882 (HY-101127) .
    Rolinsatamab talirine
  • HY-P10757
    DTX-P7

    		Peptide-Drug Conjugate (PDC) PERK Antibody-Drug Conjugates (ADCs) HSP Eukaryotic Initiation Factor (eIF) Apoptosis Cancer
    DTX-P7 is a peptide-drug conjugate. DTX-P7, composed of Docetaxel (DTX, HY-B0011) and a heptapeptide (P7), induces unfolded protein response and subsequent apoptosis by degrading Hsp90 .
    DTX-P7
  • HY-158199
    BCN-HS-PEG2-bis(PNP)

    		ADC Linker Cancer
    BCN-HS-PEG2-bis(PNP) (Compound 62) is a p-nitrophenyl-containing ADC linker that can be used to further couple ADC cytotoxins with peptide linkers. BCN-HS-PEG2-bis(PNP) can conjugate with vc-PABC-MMAE (HY-15162) to form Drug-Linker Conjugates for ADC .
    BCN-HS-PEG2-bis(PNP)
  • HY-125586
    β-Amanitin

    		DNA/RNA Synthesis ADC Cytotoxin Cancer
    β-Amanitin is a cyclic peptide toxin in the poisonous Amanita phalloides mushroom. β-Amanitin inhibits inhibits eukaryotic RNA polymerase II and III. β-Amanitin inhibits protein synthesis. β-Amanitin can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .
    β-Amanitin
  • HY-P10770
    P-ESBP-DOX

    		Peptide-Drug Conjugate (PDC) Antibody-Drug Conjugates (ADCs) E-Selectin Cardiovascular Disease Cancer
    P-ESBP-DOX is a HPMA copolymer-drug conjugate, which is consistituted of the E-selectin binding peptide and the Doxorubicin (HY-15142). P-ESBP-DOX exhibits cytotoxicity against TNFα-activated human vascular endothelial cells IVECs with an IC50 of 0.28 μM. P-ESBP-DOX can be used in research about tumor vasculature .
    P-ESBP-DOX
  • HY-P10762
    CBP-1008

    		Peptide-Drug Conjugate (PDC) Antibody-Drug Conjugates (ADCs) Folate Receptor (FR) TRP Channel Cancer
    CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma) .
    CBP-1008
  • HY-15582
    Auristatin E

    		Microtubule/Tubulin ADC Cytotoxin Cancer
    Auristatin E is a cytotoxic microtubule polymerization inhibitor with potent and selective antitumor activity. Auristatin E is a cytotoxin in antibody-drug conjugates (ADC). Auristatin E inhibits cell division by blocking the polymerisation of tubulin, promising for research in B-cell malignancies. Auristatin E, a synthetic analogue of the Dolastatin 10 (HY-15580), is linear peptides comprised of four amino acids .
    Auristatin E
  • HY-P10760
    PhAc-ALGP-Dox

    		Peptide-Drug Conjugate (PDC) Antibody-Drug Conjugates (ADCs) Cancer
    PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
    PhAc-ALGP-Dox
  • HY-P4073
    ANG1005

    GRN1005; Paclitaxel trevatide

    		 Peptide-Drug Conjugate (PDC) Cancer
    ANG1005 (Paclitaxel trevatide) is a brain-penetrating peptide-drug conjugate. ANG1005, a taxane derivative, consists of three paclitaxel (HY-B0015) molecules covalently linked to Angiopep-2, designed to cross the blood-brain and blood-cerebrospinal barriers and to penetrate malignant cells via low density lipoprotein receptor-related protein (LRP1) transport system .
    ANG1005
  • HY-138298A
    Trastuzumab deruxtecan
    2 Publications Verification

    DS-8201; DS-8201a

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan
  • HY-138298
    Trastuzumab deruxtecan (solution)
    2 Publications Verification

    DS-8201 (solution); DS-8201a (solution)

    		 Antibody-Drug Conjugates (ADCs) EGFR Cancer
    Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer .
    Trastuzumab deruxtecan (solution)
  • HY-164992
    Trastuzumab MMAE

    		Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Trastuzumab MMAE is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab MMAE is composed of a humanized anti-HER2 antibody Trastuzumab (HY-P9907), an enzymatically cleavable peptide-linker Valine-citrulline, a tubulin inhibitor Monomethyl auristatin E (MMAE; HY-15162). Trastuzumab MMAE can be used for the research of HER2-positive breast cancer .
    Trastuzumab MMAE

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: